load

Valenta Pharm’s Ingavirin® Wins Consumer Health Choice Awards 2017

Valenta Pharm’s Ingavirin® Wins Consumer Health Choice Awards 2017

25.09.2017

On September 19, 2017, Moscow hosted the first Russian awarding ceremony for the Consumer Health Choice Awards 2017 organized by QuintilesIMS International Corporation.

Valenta Pharm’s Ingavirin® became the winner in the Medicine No.1 in Group 01B (Anti-Cold) category. The winner was determined in compliance with the QuintilesIMS PharmaTrend, MAT’6 2017 internal database rating based on the highest product sales rates. The award was granted in five categories, and namely: Best Anti-Cold Medicines, Medicines for Sore Throat, Systemic Analgesics, Anti-Cough Medicines and Medicines for Muscle Pain.

The key idea of this event is to congratulate the leaders of the industry sectors chosen by QuintilesIMS and inform consumers of the best medicines in the Russian market.

QuintilesIMS is the world’s largest company providing its services in pharmaceutical and biopharmaceutical development and corporate outsourcing. The company is also one of the world’s leaders in information and technology solutions for the healthcare industry.

Ingavirin® is an innovative domestic over-the-counter antiviral agent with a unique mechanism of action and a wide range of antiviral activities. The product is approved for adults and children of 7+ years old. Russia’s Ministry of Healthcare has included this product into the Register of Vital and Essential Drugs (VEDs).

Ingavirin® is acknowledged by the professional medical community. It is:

- The most frequently prescribed medicine for the treatment of flu and other ARVIs of non-influenza etiology among general practitioners*.

- The most frequently prescribed medicine for acute upper respiratory tract infections among ENT specialists**.

For detailed prescribing information on this product, please visit Valenta’s official website: http://www.valentapharm.com/ingavirin/

  • *- according to the data from Ipsos Comcon – Prindex, April 2017.
  • **- according to the data from Ipsos Comcon – Prindex, April 2017.